Hepatic candidiasis has been increasingly recognized as a variant of disseminated candidiasis in immunocompromised patients. Five leukemic patients with antemortem diagnosis of hepatic candidiasis are described, and 32 additional cases reported in the literature are reviewed. Cultures of the liver and/or spleen and blood cultures usually give negative results; histopathologic demonstration of Candida organisms in tissue specimens is necessary for a definitive diagnosis. Response to conventional therapy with amphotericin B is poor, and 34.4 percent of the patients died with evidence of active fungal disease. Liposome-encapsulated amphotericin B, which has been successfully used in a limited number of patients with invasive fungal disease, may be an effective and relatively nontoxic drug.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0002-9343(87)90492-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of lipid nanoparticles-based vaccine to protect against vulvovaginal candidiasis (VVC): Implications for women's reproductive health.
Life Sci
January 2025
Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraidah 51452, Saudi Arabia.
Aims: Vulvovaginal candidiasis (VVC) is a common women's health issue, with rising antifungal resistance. This study was aimed to prepare and evaluate the efficacy of a lipid nanoparticle-based vaccine in a murine model of VVC.
Materials And Methods: Dried and reconstituted vesicles containing C.
Optimizing Mucoadhesive Film-Forming Spray for Efficient Oral Delivery of Fluconazole in Candidiasis Treatment.
Cureus
September 2024
Department of Pharmaceutics, College of Pharmacy, University of Baghdad, Baghdad, IRQ.
Buccal candidiasis has become increasingly prevalent in recent years, with being the primary causative organism. While systemic fluconazole is an effective treatment, its use is associated with adverse effects such as gastric upset, hepatic failure, and potential drug interactions. Therefore, the development of local fluconazole treatment presents a promising solution to these challenges.
View Article and Find Full Text PDFArticle Synopsis
- Bimekizumab, a new FDA-approved treatment for moderate to severe plaque psoriasis, targets both IL-17A and IL-17F to improve patient quality of life.
- A group of experts reviewed 110 studies on bimekizumab's safety, narrowing it down to 15 relevant articles to create consensus statements on its use.
- Overall, bimekizumab shows a favorable safety profile compared to other biologics, although it has a slightly higher risk of oral candidiasis.
Pharmacokinetic evaluation of ibrexafungerp for the treatment of vulvovaginal candidiasis and beyond.
Expert Opin Drug Metab Toxicol
August 2024
Department of Internal Medicine Division of Infectious Diseases, University of California-Davis Medical Center, Sacramento, CA, USA.
Introduction: Ibrexafungerp is a new triterpenoid antifungal agent with activity against a variety of fungal species, including spp. and echinocandin-resistant spp.
Areas Covered: This evaluation will summarize currently available clinical evidence on the use of ibrexafungerp in the treatment/prevention of vulvovaginal candidiasis (VVC) and detail the mechanism of action, pharmacokinetic/pharmacodynamic parameters, and ongoing/latest research involving ibrexafungerp.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!